Top

Published in:

01-01-2010 | Clinical trial

Assessment of false-negative cases of breast MR imaging in women with a familial or genetic predisposition

Authors: Inge-Marie A. Obdeijn, Claudette E. Loo, Adriana J. Rijnsburger, Martin N. J. M. Wasser, Elisabeth Bergers, Theo Kok, Jan G. M. Klijn, Carla Boetes

Published in: Breast Cancer Research and Treatment | Issue 2/2010

Abstract

In order to assess the characteristics of malignant breast lesions those were not detected during screening by MR imaging. In the Dutch MRI screening study (MRISC), a non-randomized prospective multicenter study, women with high familial risk or a genetic predisposition for breast cancer were screened once a year by mammography and MRI and every 6 months with a clinical breast examination (CBE). The false-negative MR examinations were subject of this study and were retrospectively reviewed by two experienced radiologists. From November 1999 until March 2006, 2,157 women were eligible for study analyses. Ninety-seven malignant breast tumors were detected, including 19 DCIS (20%). In 22 patients with a malignant lesion, the MRI was assessed as BI-RADS 1 or 2. One patient was excluded because the examinations were not available for review. Forty-three percent (9/21) of the false-negative MR cases concerned pure ductal carcinoma in situ (DCIS) or DCIS with invasive foci, in eight of them no enhancement was seen at the review. In six patients the features of malignancy were missed or misinterpreted. Small lesion size (n = 3), extensive diffuse contrast enhancement of the breast parenchyma (n = 2), and a technically inadequate examination (n = 1) were other causes of the missed diagnosis. A major part of the false-negative MR diagnoses concerned non-enhancing DCIS, underlining the necessity of screening not only with MRI but also with mammography. Improvement of MRI scanning protocols may increase the detection rate of DCIS. The missed and misinterpreted cases are reflecting the learning curve of a multicenter study.

Kiemeney LA, Lemmers FA, Verhoeven RH, Aben KK, Honing C, de Nooijer J, Peeters PH, Visser O, Vlems FA (2008) The risk of cancer in the Netherlands. Ned Tijdschr Geneeskd 152(41):2233–2436PubMed

Antoniou A, Pharoah PDP, Narod S, Risch HA, Eyfjord JE, Hopper JL (2003) Average risk of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72:1117–1130PubMedCrossRef

Kolb TM, Lichy J, Newhouse JH (2002) Comparison of the performance of screening mammography, physical examination, and breast US and evaluation of factors that influence them: an analysis of 27,825 patient evaluation. Radiology 225(1):165–175PubMedCrossRef

Brekelmans CT, Seynave C, Bartels CC, Tilanus-Linthorst MM, Meijers-Heijboer EJ, Crepin CM, van Geel AA, Menke M, Verhoog LC, van den Ouweland A, Obdeijn IM, Klijn JG, Rotterdam committee for medical, genetic counselling (2001) Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk. J Clin Oncol 19(4):924–930PubMed

Tilanus-Linthorst M, Verhoog L, Obdeijn IM, Bartels K, Menke-Pluymers M, Eggermont A, Klijn J, Meijers-Heijboer H, van der Kwast T, Brekelmans C (2002) A BRCA1/2 mutation, high breast density and prominent pushing margins of a tumor independently contribute to a frequent false-negative mammography. Int J Cancer 102:91–95PubMedCrossRef

Lakhani SR, Jacquemier J, Sloane JP, Guterson BA, Anderson TJ, van de Vijver MJ, Farid LM, Venter D, Antoniou A, Storfer A, Smyth E, Steel M, Haites N, Scott RJ, Goldgar D, Neuhausen S, Daly PA et al (1998) Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 90:1138–1145PubMedCrossRef

Komenaka IK, Ditkoff B-A, Joseph K-A, Russo D, Choroochurn P, Ward M, Horowitz E, El-Tamer MB, Schnabel FR (2004) The development of interval breast malignancies in patients with BRCA mutations. Cancer 100:2079–2083PubMedCrossRef

Harms SE, Flamig DP, Hesley KL, Meiches MD, Jensen RA, Evans WP, Savino DA, Wells RV (1993) MR imaging if the breast with rotating delivery of excitation off resonance: clinical experience with pathologic correlation. Radiology 187(2):493–501PubMed

Heywang-Kobrunner SH (1994) Contrast-enhanced magnetic resonance imaging of the breast. Invest Radiol 29:94–104PubMedCrossRef

10.

Orel SG, Schnall MD (2001) MR Imaging of the breast for the detection, diagnosis, and staging of breast cancer. Radiology 220:13–30PubMed

11.

Tilanus-Linthorst MMA, Obdeijn AIM, Bartels CCM, de Koning HJ, Oudkerk M (2000) First experiences in screening women at high risk for breast cancer with MR imaging. Breast Cancer Res Treat 63:53–60PubMedCrossRef

12.

Kuhl CK, Schmutzler RK, Leutner CC, Kempe A, Wardelmann E, Hocke A, Maringa M, Pfeifer U, Krebs D, Schild HH (2000) Breast imaging screening in 192 women proved or suspected to be carriers of a breast cancer susceptibility gene: preliminary results. Radiology 215:267–279PubMed

13.

Warner E, Plewes DB, Shumak RS, Catzavelos GC, Prospero Di LS, Yaffe MJ, Goel V, Ramsey E, Chart PL, Cole DCE, Taylor GA, Cutrara M, Samuels TH, Murphy JP, Narod SA (2001) Comparison of breast magnetic resonance imaging, mammography, and ultrasound for surveillance of women at high risk for hereditary breast cancer. J Clin Oncol 19:3524–3531PubMed

14.

Podo E, Sardanelli F, Canese R, D’Agnolo, Natali PG, Crecco M, Grandinetti ML, Musumeci R, Trecate G, Bergonzi S, De Simone T, Pasisni B, Manuokian S, Spatti GB, Vergnaghi D, Morassut S, Panizza P, Del Maschio A (2002) The Italian multi-center project on evaluation of MRI and other imaging modalities in early detection of breast cancer in subjects at high genetic risk. J Exp Clin Cancer Res 21(Suppl 3):115–124PubMed

15.

Kriege M, Brekelmans CTM, Boetes C, Besnard PE, Zonderland HM, Obdeijn IM, Manoliu RA, Kok T, Peterse H, Tilanus-linthorst MMA, Muller SA, Meijer S, Oosterwijk JC, Beex LVAM, Tollenaar RAEM, de Koning HJ, Rutgers EJT, Klijn JGM (2004) Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 351(5):427–437PubMedCrossRef

16.

Warner E, Plewes DB, Hill KA, Causer PA, Zubovits JT, Jong RA, Cutrara MR, DeBoer G, Yaffe MJ, Messner SJ, Meschino WS, Piron CA, Narod SA (2004) Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 292:1317–1325PubMedCrossRef

17.

MARIBS study group (2005) Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer; a prospective multicenter cohort study (MARIBS). Lancet 365:1769–1778CrossRef

18.

Kuhl CK, Schrading S, Leutner CC, Morakkabati-Spitz N, Wardelmann E, Fimmers R, Kuhn, Schild HH (2005) Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk of breast cancer. J Clin Oncol 23:8469–8476PubMedCrossRef

19.

Sardanelli F, Podo F, D’Agnolo G, Verdecchia A, Santaquilana M, Musumeci R, Trecate G, Manoukian S, Morassut S, de Giacomi C, Federico M, Cortesi L, Corcione S, Cirillo S, Marra V (2007) Multicenter comparative multimodality surveillance of women at genetic-familial high risk for breast cancer (HIBCRIT Study): interim results. Radiology 242:698–715PubMedCrossRef

20.

Sardanelli F, Podo F (2007) Breast imaging in women at high risk of breast cancer. Is something changing in early breast cancer detection? Eur Radiol 17:873–887PubMedCrossRef

21.

Warner E, Messersmith H, Causer P, Eisen A, Shumal R, Plewes D (2008) Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer. Ann Intern Med 148:671–679PubMed

22.

Breast Imaging Reporting and Data System (BI-RADS) (2003) Ultrasound, mammography and magnetic resonance atlas. American College of Radiology, Reston, VA

23.

Kuhl CK, Schrading S, Bieling HB, Wardelmann E, Leutner CC, Koenig R, Kuhn W, Schild HH (2007) MRI for diagnosis of pure ductal carcinoma in situ: a prospective observational study. Lancet 370:485–492PubMedCrossRef

24.

Schouten van der Velden AP, Schlooz-Vries MS, Boetes C, Wobbes T (2009) Magnetic resonance imaging of ductal carcinoma in situ: what is its clinical application? A review. Am J Surg 198(2):262–269PubMedCrossRef

25.

Berg WA, Guttierrez L, NessAiver MS, Carter WB, Bhargavan M, Lewis RS, Ioffe OB (2004) Diagnostic accuracy of mammography, clinical examination, US, and MR Imaging in preoperative assessment of breast cancer. Radiology 233:830–849PubMedCrossRef

26.

Menell JH, Morris EA, Dershaw DD, Abramson AF, Brogi E, Liberman L (2005) Determination of the presence and extent of pure ductal carcinoma in situ by mammography and magnetic resonance imaging. Breast J 6:382–390CrossRef

27.

Facius M, Renz DM, Neubauer H, Böttcher J, Gajda M, Camara O, Kaiser WA (2007) Characteristics of ductal carcinoma in situ in magnetic resonance imaging. Clin Imaging 3:394–400CrossRef

28.

Rosen EL, Smith-Foley SA, DeMartini WB, Eby PR, Peacock S, Lehman CD (2008) BI-RADS MRI enhancement characteristics of ductal carcinoma in situ. Breast J 13(6):545–550CrossRef

29.

Vogl G, Dietze O, Hauser-Kronberger C (2005) Angiogenic potential of ductal carcinoma in situ (DCIS) of human breast. Histopathology 47:617–624PubMedCrossRef

30.

Guidi AJ, Schnitt SJ, Fischer L, Tognazzi K, Harris JR, Dvorak HF, Brown LF (1997) Vascular permeability factor (Vascular endothelial growth factor) expression and angiogenesis in patients with ductal carcinoma in situ of the breast. Cancer 80(10):1945–1953PubMedCrossRef

31.

Santamaria G, Velasco M, Farrus B, Zanon G, Fernandez PL (2008) Pre-operative MRI of pure intraductal breast carcinoma: a valuable adjunct to mammography in assessing cancer extent. Breast 17:186–194PubMedCrossRef

32.

Rausch DR, Hendrick RE (2006) How to optimize clinical breast MR Imaging practices and techniques on your 1.5-Tesla system. RadioGraphics 26:1469–1484PubMedCrossRef

33.

Kuhl C (2007) The current status of breast MR Imaging. Radiology 244(2):356–378PubMedCrossRef

34.

Tilanus-Linthorst MM, Obdeijn IM, Hop WC, Causer PA, Leach MO, Warner E, Pointon L, Hill K, Klijn JG, Warren RM, Gilbert FJ (2007) BRCA1 mutation and young age predict fast breast cancer growth in the Dutch, United Kingdom, and Canadian magnetic resonance imaging screening trials. Clin Cancer Res 13(24):7357–7362PubMedCrossRef

35.

Warren RM, Pointon L, Thompson D, Hoff R, Gilbert FJ, Padhani A, Easton D, Lakhani SR, Leach MO, UK Magnetic Resonance Imaging in breast screening (MARIBS) Group (2005) Reading protocol for dynamic contrast-enhanced MR images of the breast: sensitivity and specificity analysis. Radiology 236(3):779–788PubMedCrossRef

Title: Assessment of false-negative cases of breast MR imaging in women with a familial or genetic predisposition
Authors: Inge-Marie A. Obdeijn
Claudette E. Loo
Adriana J. Rijnsburger
Martin N. J. M. Wasser
Elisabeth Bergers
Theo Kok
Jan G. M. Klijn
Carla Boetes
Publication date: 01-01-2010
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 2/2010
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-009-0607-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2010

Identification and characterization of two novel germ line p53 mutations in the non-LFS/non-LFL breast cancer families in Chinese population

Variation in genes required for normal mitosis and risk of breast cancer

Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA2

Are mammography recommendations in women younger than 40 related to increased risk?

The impact of preoperative breast MRI on the re-excision rate in invasive lobular carcinoma of the breast

Proliferative genes dominate malignancy-risk gene signature in histologically-normal breast tissue

Keynote webinar | Spotlight on antibody–drug conjugates in cancer